Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin in Indolent NHL
NCT00868608Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2009
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of inotuzumab ozogamicin in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Pfizer. Primary endpoint: Objective Response Rate (CR + PR) at 2 years. Started Jul 2009; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00868608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00868608.